<p>IDUs, intravenous drug users; NS, not significant.</p>a<p>data available for 400 subjects.</p>b<p>data available for 289 subjects.</p>c<p>data available for 391 subjects.</p>d<p>data available for 240 subjects.</p>e<p>data available for 385 subjects.</p>f<p>data available for 242 subjects.</p>g<p>Total number of subjects with known gender.</p>h<p>Total number of subjects with known ethnicity.</p
<p>Demographics of the study participants by NVG secondary to RVO patients, NVG secondary to DR pati...
<p><sup>a</sup> MSM, men who have sex with men; IDU, injection drug user.</p><p>Socio-demographic an...
<p>The three virulence analyses could be performed on different, albeit overlapping, subsets of the ...
<p>IQR, interquartile range; HE, heterosexual; MSM, men-who-have-sex-with-men; IDU, injection drug u...
<p>IDUs, intravenous drug users; NS, not significant.</p>a<p>data available for 63 subjects.</p>b<p>...
<p>* IDU, intravenous drug users</p><p><sup>#</sup> Partial genome</p><p>Demographic characteristics...
(A) Number of participants by counties, (B) Number of participants by age groups, (C) Number of part...
<p>HIV-negative, healthy controls (HIV-, N = 61), HIV-positive individuals without cocaine use (HIV+...
<p>Demographic and clinical information of study participants (N = 3491) (n, %).</p
<p>TB = tuberculosis.</p><p>LTBI = latent infection with <i>M</i>. <i>tuberculosis</i>.</p><p>m = ma...
<p>Demographic and clinical characteristics of participants in this study (n = 91) as compared to cl...
<p>(<u>KEY</u>: <b>Other Medications:</b> 1 = risperidone, 2 = lamotrogine, 3 = atomoxetine, 4 = que...
<p>The socio-demographic and clinical characteristics of study participants (n = 546).</p
<p>M = male, F = female.</p><p>Demographics for FHN, FHP, and total sample used in the study.</p
<p>Values presented as *mean ± SD or <sup>†</sup>N (%) or median(ICR).</p><p>Demographics and clinic...
<p>Demographics of the study participants by NVG secondary to RVO patients, NVG secondary to DR pati...
<p><sup>a</sup> MSM, men who have sex with men; IDU, injection drug user.</p><p>Socio-demographic an...
<p>The three virulence analyses could be performed on different, albeit overlapping, subsets of the ...
<p>IQR, interquartile range; HE, heterosexual; MSM, men-who-have-sex-with-men; IDU, injection drug u...
<p>IDUs, intravenous drug users; NS, not significant.</p>a<p>data available for 63 subjects.</p>b<p>...
<p>* IDU, intravenous drug users</p><p><sup>#</sup> Partial genome</p><p>Demographic characteristics...
(A) Number of participants by counties, (B) Number of participants by age groups, (C) Number of part...
<p>HIV-negative, healthy controls (HIV-, N = 61), HIV-positive individuals without cocaine use (HIV+...
<p>Demographic and clinical information of study participants (N = 3491) (n, %).</p
<p>TB = tuberculosis.</p><p>LTBI = latent infection with <i>M</i>. <i>tuberculosis</i>.</p><p>m = ma...
<p>Demographic and clinical characteristics of participants in this study (n = 91) as compared to cl...
<p>(<u>KEY</u>: <b>Other Medications:</b> 1 = risperidone, 2 = lamotrogine, 3 = atomoxetine, 4 = que...
<p>The socio-demographic and clinical characteristics of study participants (n = 546).</p
<p>M = male, F = female.</p><p>Demographics for FHN, FHP, and total sample used in the study.</p
<p>Values presented as *mean ± SD or <sup>†</sup>N (%) or median(ICR).</p><p>Demographics and clinic...
<p>Demographics of the study participants by NVG secondary to RVO patients, NVG secondary to DR pati...
<p><sup>a</sup> MSM, men who have sex with men; IDU, injection drug user.</p><p>Socio-demographic an...
<p>The three virulence analyses could be performed on different, albeit overlapping, subsets of the ...